false --12-31 0001692415 0001692415 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 19, 2026

 

CO-DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

 

Commission File No. 001-38148

 

Utah   46-2609363
(State or other jurisdiction   (IRS Employer
of incorporation)   Identification Number)

 

2401 S. Foothill Drive, Suite D

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 438-1036

 

Former name or former address, if changed since last report: Not Applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.03 - Material Modification to Rights of Security Holders.

 

As previously disclosed, on November 13, 2026, at a special meeting of the stockholders of Co-Diagnostics, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by the Company’s board of directors (the “Board”) at any time within twelve months following the special meeting, without further approval or authorization of the stockholders.

 

On November 13, 2026, the Company’s Board approved a reverse stock split ratio of 1-for-25. The Company filed Articles of Amendment to the Company’s Articles of Incorporation, as amended (the “Amendment”) with the Utah Division of Corporations and Commercial Code on November 19, 2026, which will be effective at 12:01 a.m. Mountain Time on Tuesday, November 24, 2026. The Company’s shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market commencing upon market open on November 24, 2026. A copy of the Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference. This discussion is qualified in its entirety by reference to the full text of the Amendment.

 

As a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one (1) issued and outstanding share of common stock, par value $0.001 per share. The Company will not issue any fractional shares in connection with the reverse stock split. Instead, each stockholder who would otherwise be entitled to receive a fractional share will receive one whole share of common stock in lieu of such fractional share. The reverse stock split will not modify the rights or preferences of the common stock. The reverse stock split will also not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation.

 

Immediately after the reverse stock split becomes effective, there will be approximately 521,779 shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 189763 303, effective November 24, 2026, and continue to trade under the symbol “CODX.” All stock options and warrants of the Company outstanding immediately prior to the reverse stock split will be proportionally adjusted in accordance with their respective terms.

 

The Company has appointed its transfer agent, VStock Transfer, LLC, to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information set forth in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 7.01. Regulation FD. Disclosure.

 

On November 19, 2026, the Company issued a press release announcing the reverse stock split. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number   Description
3.1   Articles of Amendment to the Articles of Incorporation of Co-Diagnostics, Inc.
99.1   Press release dated November 19, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      CO-DIAGNOSTICS, INC.
         
Date: November 19, 2026   By: /s/ Daniel Bohrer
        Daniel Bohrer
        Executive Vice President Finance & Accounting (Principal Financial and Accounting Officer)